GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » aTyr Pharma Inc (FRA:471A) » Definitions » Deferred Policy Acquisition Costs

aTyr Pharma (FRA:471A) Deferred Policy Acquisition Costs


View and export this data going back to 2016. Start your Free Trial

What is aTyr Pharma Deferred Policy Acquisition Costs?

Deferred Policy Acquisition Costs only applies to banks and insurance companies.


aTyr Pharma Business Description

Industry
Traded in Other Exchanges
Address
10240 Sorrento Valley Road, Suite 300, San Diego, CA, USA, 92121
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.